secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001654954-23-008353
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech receives Nasdaq deficiency letter for bid price below $1, has 180 days to cure
--------------------------------------------------------------------------------

- Company has until Dec 19, 2023 to regain compliance by closing at $1 or more for 10 consecutive business days.
- If not cured, may qualify for another 180-day period subject to meeting other Nasdaq standards and a reverse split.
- Nasdaq listing remains fully effective; no immediate impact on trading of EDSA common shares.
- Company will monitor bid price and consider options to regain compliance, but cannot assure success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495423008353/0001654954-23-008353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495423008353/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-008353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer